Integration and dosimetric validation of a dynamic collimation system for pencil beam scanning proton therapy

Objective.To integrate a Dynamic Collimation System (DCS) into a pencil beam scanning (PBS) proton therapy system and validate its dosimetric impact.Approach.Uncollimated and collimated treatment fields were developed for clinically relevant targets using an in-house treatment plan optimizer and an experimentally validated Monte Carlo model of the DCS and IBA dedicated nozzle (DN) system. The dose reduction induced by the DCS was quantified by calculating the mean dose in 10- and 30-mm two-dimensional rinds surrounding the target. A select number of plans were then used to experimentally validate the mechanical integration of the DCS and beam scanning controller system through measurements with the MatriXX-PT ionization chamber array and EBT3 film. Absolute doses were verified at the central axis at various depths using the IBA MatriXX-PT and PPC05 ionization chamber.Main results.Simulations demonstrated a maximum mean dose reduction of 12% for the 10 mm rind region and 45% for the 30 mm rind region when utilizing the DCS. Excellent agreement was observed between Monte Carlo simulations, EBT3 film, and MatriXX-PT measurements, with gamma pass rates exceeding 94.9% for all tested plans at the 3%/2 mm criterion. Absolute central axis doses showed an average verification difference of 1.4% between Monte Carlo and MatriXX-PT/PPC05 measurements.Significance.We have successfully dosimetrically validated the delivery of dynamically collimated proton therapy for clinically relevant delivery patterns and dose distributions with the DCS. Monte Carlo simulations were employed to assess dose reductions and treatment planning considerations associated with the DCS.

Design, testing and characterization of a proton central axis alignment device for the Dynamic Collimation System

OBJECTIVE

Proton therapy conformity has improved over the years by evolving from passive scattering to spot scanning delivery technologies with smaller proton beam spot sizes. Ancillary collimation devices, such the Dynamic Collimation System (DCS), further improves high dose conformity by sharpening the lateral penumbra. However, as spot sizes are reduced, collimator positional errors play a significant impact on the dose distributions and hence accurate collimator to radiation field alignment is critical. 
Approach. The purpose of this work was to develop a system to align and verify coincidence between the center of the DCS and the proton beam central axis. The Central Axis Alignment Device (CAAD) is composed of a camera and scintillating screen-based beam characterization system. Within a light-tight box, a 12.3-megapixel camera monitors a P43/Gadox scintillating screen via a 45⁰ first-surface mirror. When a collimator trimmer of the DCS is placed in the uncalibrated center of the field, the proton radiation beam continuously scans a 7x7 cm² square field across the scintillator and collimator trimmer while a 7 second exposure is acquired. From the relative positioning of the trimmer to the radiation field, the true center of the radiation field can be calculated.
Main results. The CAAD can calculate the offset between the proton beam radiation central axis and the DCS central axis within 0.054 mm accuracy and 0.075 mm reproducibility.
Significance. Using the CAAD, the DCS is now able to be aligned accurately to the proton radiation beam central axis and no longer relies on an x-ray source in the gantry head which is only validated to within 1.0 mm of the proton beam.&#xD.

Dosimetric delivery validation of dynamically collimated pencil beam scanning proton therapy

Objective. Pencil beam scanning (PBS) proton therapy target dose conformity can be improved with energy layer-specific collimation. One such collimator is the dynamic collimation system (DCS), which consists of four nickel trimmer blades that intercept the scanning beam as it approaches the lateral extent of the target. While the dosimetric benefits of the DCS have been demonstrated through computational treatment planning studies, there has yet to be experimental verification of these benefits for composite multi-energy layer fields. The objective of this work is to dosimetrically characterize and experimentally validate the delivery of dynamically collimated proton therapy with the DCS equipped to a clinical PBS system.Approach. Optimized single field, uniform dose treatment plans for 3 × 3 × 3 cm³target volumes were generated using Monte Carlo dose calculations with depths ranging from 5 to 15 cm, trimmer-to-surface distances ranging from 5 to 18.15 cm, with and without a 4 cm thick polyethylene range shifter. Treatment plans were then delivered to a water phantom using a prototype DCS and an IBA dedicated nozzle system and measured with a Zebra multilayer ionization chamber, a MatriXX PT ionization chamber array, and Gafchromic™ EBT3 film.Main results. For measurements made within the SOBPs, average 2D gamma pass rates exceeded 98.5% for the MatriXX PT and 96.5% for film at the 2%/2 mm criterion across all measured uncollimated and collimated plans, respectively. For verification of the penumbra width reduction with collimation, film agreed with Monte Carlo with differences within 0.3 mm on average compared to 0.9 mm for the MatriXX PT.Significance. We have experimentally verified the delivery of DCS-collimated fields using a clinical PBS system and commonly available dosimeters and have also identified potential weaknesses for dosimeters subject to steep dose gradients.

The dosimetric enhancement of GRID profiles using an external collimator in pencil beam scanning proton therapy

PURPOSE

The radiobiological benefits afforded by spatially fractionated (GRID) radiation therapy pairs well with the dosimetric advantages of proton therapy. Inspired by the emergence of energy-layer specific collimators in pencil beam scanning (PBS), this work investigates how the spot spacing and collimation can be optimized to maximize the therapeutic gains of a GRID treatment while demonstrating the integration of a dynamic collimation system (DCS) within a commercial beam line to deliver GRID treatments and experimentally benchmark Monte Carlo calculation methods.

METHODS

GRID profiles were experimentally benchmarked using a clinical DCS prototype that was mounted to the nozzle of the IBA Dedicated Nozzle system. Integral depth dose (IDD) curves and lateral profiles were measured for uncollimated and GRID-collimated beamlets. A library of collimated GRID dose distributions were simulated by placing beamlets within a specified uniform grid and weighting the beamlets to achieve a volume-averaged tumor cell survival equivalent to an open field delivery. The healthy tissue sparing afforded by the GRID distribution was then estimated across a range of spot spacings and collimation widths, which were later optimized based on the radiosensitivity of the tumor cell line and the nominal spot size of the PBS system. This was accomplished by using validated models of the IBA Universal and Dedicated nozzles.

RESULTS

Excellent agreement was observed between the measured and simulated profiles. The IDDs matched above 98.7% when analyzed using a 1%/1 mm gamma criteria with some minor deviation observed near the Bragg peak for higher beamlet energies. Lateral profile distributions predicted using Monte Carlo methods agreed well with the measured profiles; a gamma passing rate of 95% or higher was observed for all in-depth profiles examined using a 3%/2 mm criteria. Additional collimation was shown to improve PBS GRID treatments by sharpening the lateral penumbra of the beamlets but creates a tradeoff between enhancing the valley-to-peak ratio of the GRID delivery and the dose-volume effect. The optimal collimation width and spot spacing changed as a function of the tumor cell radiosensitivity, dose, and spot size. In general, a spot spacing below 2.0 cm with a collimation less than 1.0 cm provided a superior dose distribution among the specific cases studied.

CONCLUSIONS

The ability to customize a GRID dose distribution using different collimation sizes and spot spacings is a useful advantage, especially to maximize the overall therapeutic benefit. In this regard, the capabilities of the DCS, and perhaps alternative dynamic collimators, can be used to enhance GRID treatments. Physical dose models calculated using Monte Carlo methods were experimentally benchmarked in water and were found to accurately predict the respective dose distributions of uncollimated and DCS-collimated GRID profiles. This article is protected by copyright. All rights reserved.

Development and validation of the Dynamic Collimation Monte Carlo simulation package for pencil beam scanning proton therapy

PURPOSE

The aim of this work was to develop and experimentally validate a Dynamic Collimation Monte Carlo (DCMC) simulation package specifically designed for the simulation of collimators in pencil beam scanning proton therapy (PBS-PT). The DCMC package was developed using the TOPAS Monte Carlo platform and consists of a generalized PBS source model and collimator component extensions.

METHODS

A divergent point-source model of the IBA dedicated nozzle (DN) at the Miami Cancer Institute (MCI) was created and validated against on-axis commissioning measurements taken at MCI. The beamline optics were mathematically incorporated into the source to model beamlet deflections in the X and Y directions at the respective magnet planes. Off-axis measurements taken at multiple planes in air were used to validate both the off-axis spot size and divergence of the source model. The DCS trimmers were modeled and incorporated as TOPAS geometry extensions that linearly translate and rotate about the bending magnets. To validate the collimator model, a series of integral depth dose (IDD) and lateral profile measurements were acquired at MCI and used to benchmark the DCMC performance for modeling both pristine and range shifted beamlets. The water equivalent thickness (WET) of the range shifter was determined by quantifying the shift in the depth of the 80% dose point distal to the Bragg peak between the range shifted and pristine uncollimated beams.

RESULTS

A source model of the IBA DN system was successfully commissioned against on- and off-axis IDD and lateral profile measurements performed at MCI. The divergence of the source model was matched through an optimization of the source-to-axis distance and comparison against in-air spot profiles. The DCS model was then benchmarked against collimated IDD and in-air and in-phantom lateral profile measurements. Gamma analysis was used to evaluate the agreement between measured and simulated lateral profiles and IDDs with 1%/1 mm criteria and a 1% dose threshold. For the pristine collimated beams, the average 1%/1 mm gamma pass rates across all collimator configurations investigated were 99.8% for IDDs and 97.6% and 95.2% for in-air and in-phantom lateral profiles. All range shifted collimated IDDs passed at 100% while in-air and in-phantom lateral profiles had average pass rates of 99.1% and 99.8%, respectively. The measured and simulated WET of the polyethylene range shifter was determined to be 40.9 and 41.0 mm, respectively.

CONCLUSIONS

We have developed a TOPAS-based Monte Carlo package for modeling collimators in PBS-PT. This package was then commissioned to model the IBA DN system and DCS located at MCI using both uncollimated and collimated measurements. Validation results demonstrate that the DCMC package can be used to accurately model other aspects of a DCS implementation via simulation.

An evaluation of the stability of image quality parameters of Elekta X-ray volume imager and iViewGT imaging systems

INTRODUCTION

A robust image quality assurance and analysis methodology for image-guided localization systems is crucial to ensure the accurate localization and visualization of target tumors. In this study, the long-term stability of selected image parameters was assessed and evaluated for the cone-beam computed tomography (CBCT) mode, planar radiographic kV mode, and the radiographic MV mode of an Elekta VersaHD.

MATERIALS AND METHODS

The CATPHAN, QckV-1, and QC-3 phantoms were used to evaluate the image quality parameters. The planar radiographic images were analyzed in PIPSpro™ with spatial resolution (f30, f40, f50), contrast to noise ratio (CNR) and noise being recorded. For XVI CBCT, Head and Neck Small20 (S20) and Pelvis Medium20 (M20) standard acquisition modes were evaluated for uniformity, noise, spatial resolution, and HU constancy. Dose and kVp for the XVI were recorded using the Unfors RaySafe Xi system with the R/F low detector for the kV planar radiographic mode. For each metric, values were normalized to the mean and the standard deviations were recorded.

RESULTS

A total of 30 measurements were performed on a single Elekta VersaHD linear accelerator over an 18-month period without significant adjustment or recalibration to the XVI or iViewGT systems during the evaluated time frame. For the planar radiographic spatial resolution, the normalized standard deviation values of the f30, f40, and f50 were 0.004, 0.003, and 0.003 and 0.015, 0.009, and 0.017 for kV and MV, respectively. The average recorded dose for kV was 67.96 μGy. The standard deviations of the evaluated metrics for the S20 acquisition were 0.083(f30), 0.058(f40), 0.056(f50), 0.021(Water/poly-HU constancy), 0.029(uniformity) and 0.028(noise). The standard deviations for the M20 acquisition were 0.093(f30), 0.043(f40), 0.037(f50), 0.016(Water/poly-HU constancy), 0.010(uniformity) and 0.011(Noise).

CONCLUSION

A study was performed to assess the stability of the basic image quality parameters recommended by TG-142 for the Elekta XVI and iViewGT imaging systems. The two systems show consistent imaging and dosimetric properties over the evaluated time frame.

Comparison of initial patient setup accuracy between surface imaging and three point localization: A retrospective analysis

Purpose

Historically, the process of positioning a patient prior to imaging verification used a set of permanent patient marks, or tattoos, placed subcutaneously. After aligning to these tattoos, plan specific shifts are applied and the position is verified with imaging, such as cone‐beam computed tomography (CBCT). Due to a variety of factors, these marks may deviate from the desired position or it may be hard to align the patient to these marks. Surface‐based imaging systems are an alternative method of verifying initial positioning with the entire skin surface instead of tattoos. The aim of this study was to retrospectively compare the CBCT‐based 3D corrections of patients initially positioned with tattoos against those positioned with the C‐RAD CatalystHD surface imager system.

Methods

A total of 6000 individual fractions (600–900 per site per method) were randomly selected and the post‐CBCT 3D corrections were calculated and recorded. For both positioning methods, four common treatment site combinations were evaluated: pelvis/lower extremities, abdomen, chest/upper extremities, and breast. Statistical differences were evaluated using a paired sample Wilcoxon signed‐rank test with significance level of <0.01.

Results

The average magnitudes of the 3D shift vectors for tattoos were 0.9 ± 0.4 cm, 1.0 ± 0.5 cm, 0.9 ± 0.6 cm and 1.4 ± 0.7 cm for the pelvis/lower extremities, abdomen, chest/upper extremities and breast, respectively. For the CatalystHD, the average magnitude of the 3D shifts for the pelvis/lower extremities, abdomen, chest/upper extremities and breast were 0.6 ± 0.3 cm, 0.5 ± 0.3 cm, 0.5 ± 0.3 cm and 0.6 ± 0.2 cm, respectively. Statistically significant differences (P < 0.01) in the 3D shift vectors were found for all four sites.

Conclusion

This study shows that the overall 3D shift corrections for patients initially aligned with the C‐RAD CatalystHD were significantly smaller than those aligned with subcutaneous tattoos. Surface imaging systems can be considered a viable option for initial patient setup and may be preferable to permanent marks for specific clinics and patients.

Characterization of air temperature in modern ion chambers due to phantom geometry and ambient temperature changes

PURPOSE

Temperature and pressure corrections are necessary to account for the varying mass of air in the sensitive volume of a vented ionization chamber (IC) when performing absolute dose measurements. Locations commonly used to measure the presumed IC air temperature may not accurately represent the chamber cavity air temperature, and phantoms undergoing temperature changes further compound the problem. Prior studies have characterized thermal equilibrium in separate phantoms for Farmer chambers alone. However, the purpose of this study was to characterize the cavity air temperature dependence on changes in the ambient temperature and phantom geometry configuration for a wider and more modern variety of chambers to determine if previously published wait times apply to these chambers as well.

METHODS

Thermal conduction properties were experimentally investigated by modifying a PTW 0.3 cm(3) Semiflex IC with a thermocouple replacing the central electrode. Air cavity temperature versus time was recorded in three phantom geometries characteristic of common absolute dose measurements. The phantoms were (15 ± 1) °C before measurement with an IC at the treatment vault temperature of (21 ± 1) °C. Simulations were conducted to provide a theoretical basis for the measurements and to simulate temperature response of a PTW PinPoint® and Farmer chamber. The simulation methods were first validated by comparison with measured Semiflex chamber thermal response curves before extension to the other chambers.

RESULTS

Two thermal equilibria curves were recorded on different time scales. IC temperature initially dropped to the colder phantom temperature but subsequently increased as the phantom itself equilibrated with the warmer room temperature. In a large phantom of dimensions (25.5 × 25.5 × 23.4) cm(3), 3 min was required before the IC temperature reached within 0.5 °C of its equilibrium within the phantom. Similarly, wait times of 2 min were needed for 7.5 and 2 cm slab phantoms.

CONCLUSIONS

Recording of temperature in the phantom was deemed far more accurate than measurement in ambient air due to the air cavity thermally equilibrating with phantom temperature instead of the vented ambient air. Wait times of 3 and 2 min are needed for a cube and 7.5 cm slab phantom, respectively, to achieve 0.2% dosimetric accuracy (temperature accuracy of 0.5 °C). Chamber volume alone did not determine wait times, as a 0.3 cm(3) IC required a longer wait time than a Farmer chamber, suggesting wall thickness as an important variable as well.

An evaluation of the stability of image-quality parameters of Varian on-board imaging (OBI) and EPID imaging systems

Quality assurance (QA) of the image quality for image‐guided localization systems is crucial to ensure accurate visualization and localization of regions of interest within the patient. In this study, the temporal stability of selected image parameters was assessed and evaluated for kV CBCT mode, planar radiographic k V, and MV modes. The motivation of the study was to better characterize the temporal variability in specific image‐quality parameters. The CATPHAN, QckV‐1, and QC‐3 phantoms were used to evaluate the image‐quality parameters of the imaging systems on a Varian Novalis Tx linear accelerator. The planar radiographic images were analyzed in PIPSpro with high‐contrast spatial resolution (f30,f40,f50lp/mm) being recorded. For OBI kV CBCT, high‐quality head full‐fan acquisition and pelvis half‐fan acquisition modes were evaluated for uniformity, noise, spatial resolution, HU constancy, and geometric distortion. Dose and X‐ray energy for the OBI were recorded using the Unfors RaySafe Xi system with the R/F High Detector for kV planar radiographic and the CT detector for kV CBCT. Dose for the MV EPID was recorded using a PTW975 Semiflex ion chamber, PTW UNIDOS electrometer, and CNMC Plastic Water. For each image‐quality parameter, values were normalized to the mean, and the normalized standard deviations were recorded to evaluate the parameter's temporal variability. For planar radiographic modes, the normalized standard deviations of the spatial resolution (f30,f40,& f50) were 0.015, 0.008, 0.004 lp/mm and 0.006, 0.009, 0.018 lp/mm for the kV and MV, respectively. The normalized standard deviation of dose for kV and MV were 0.010 mGy and 0.005 mGy, respectively. The standard deviations for full‐and half‐fan kV CBCT modes were averaged together. The following normalized standard deviations for each kV CBCT parameter were: 0.075 HU (uniformity), 0.071 HU (noise), 0.006 mm (AP‐geometric distortion), 0.005 mm (LAT‐geometric distortion), 0.058 mm (slice thickness), 0.124 (f50), 0.031 (HU constancy – Lung), 0.063 (HU constancy – Water), 0.020 (HU constancy – Bone), 0.006 mGy (Dose – Center), 0.004 mGy (Dose –Periphery). Using control chart analysis, institutional QA tolerances were reported as warning and action thresholds based on 1σ and 2σ thresholds. A study was performed to characterize the stability of image‐quality parameters recommended by AAPM Task Group‐142 for the Varian OBI and EPID imaging systems. Both imaging systems show consistent imaging and dosimetric properties over the evaluated time frame.

PACS number: 87.10.‐e

Development of image quality assurance measures of the ExacTrac localization system using commercially available image evaluation software and hardware for image-guided radiotherapy

Quality assurance (QA) of the image quality for image‐guided localization systems is crucial to ensure accurate visualization and localization of target volumes. In this study, a methodology was developed to assess and evaluate the constancy of the high‐contrast spatial resolution, dose, energy, contrast, and geometrical accuracy of the BrainLAB ExacTrac system. An in‐house fixation device was constructed to hold the QCkV‐1 phantom firmly and reproducibly against the face of the flat panel detectors. Two image sets per detector were acquired using ExacTrac preset console settings over a period of three months. The image sets were analyzed in PIPSpro and the following metrics were recorded: high‐contrast spatial resolution (f30,f40,f50 (lp/mm)), noise, and contrast‐to‐noise ratio. Geometrical image accuracy was evaluated by assessing the length between to predetermined points of the QCkV‐1 phantom. Dose and kVp were recorded using the Unfors RaySafe Xi R/F Detector. The kVp and dose were evaluated for the following: Cranial Standard (CS) (80 kV,80 mA,80 ms), Thorax Standard (TS) (120 kV,160 mA,160 ms), Abdomen Standard (AS) (120 kV,160 mA,130 ms), and Pelvis Standard (PS) (120 kV,160 mA,160 ms). With regard to high‐contrast spatial resolution, the mean values of the f30 (lp/mm), f40 (lp/mm) and f50 (lp/mm) for the left detector were 1.39±0.04,1.24±0.05, and 1.09±0.04, respectively, while for the right detector they were 1.38±0.04,1.22±0.05, and 1.09±0.05, respectively. Mean CNRs for the left and right detectors were 148±3 and 143±4, respectively. For geometrical accuracy, both detectors had a measured image length of the QCkV‐1 of 57.9±0.5mm. The left detector showed dose measurements of 20.4±0.2μGy(CS), 191.8±0.7μGy(TS), 154.2±0.7μGy(AS), and 192.2±0.6μGy(PS), while the right detector showed 20.3±0.3μGy(CS), 189.7±0.8μGy(TS), 151.0±0.7μGy(AS), and 189.7±0.8μGy(PS), respectively. For X‐ray energy, the left detector (right X‐ray tube) had mean kVp readings of 81.6±0.5(CS), 122.5±0.5(TS), 122.0±0.8(AS), and 122.1±0.7(PS), and the right detector (left X‐ray tube) had 81.6±0.5(CS), 120.8±0.5(TS), 120.9±0.6(AS), and 121.3±0.7(PS). Run charts were created so that each parameter could be tracked over time and the constancy of the system could be monitored. A methodology was developed to assess the basic image quality parameters recommended by TG‐142 for the ExacTrac system. The ExacTrac system shows a consistent dose, kVp, high‐contrast spatial resolution, CNR, and geometrical accuracy for each detector over the evaluated timeframe.

PACS number: 87.10.‐e

On the quantification of the dosimetric accuracy of collapsed cone convolution superposition (CCCS) algorithm for small lung volumes using IMRT

Specialized techniques that make use of small field dosimetry are common practice in today's clinics. These new techniques represent a big challenge to the treatment planning systems due to the lack of lateral electronic equilibrium. Because of this, the necessity of planning systems to overcome such difficulties and provide an accurate representation of the true value is of significant importance. Pinnacle3 is one such planning system. During the IMRT optimization process, Pinnacle3 treatment planning system allows the user to specify a minimum segment size which results in multiple beams composed of several subsets of different widths. In this study, the accuracy of the engine dose calculation, collapsed cone convolution superposition algorithm (CCCS) used by Pinnacle3, was quantified by Monte Carlo simulations, ionization chamber, and Kodak extended dose range film (EDR2) measurements for 11 SBRT lung patients. Lesions were < 3.0 cm in maximal diameter and <27.0cm3 in volume. The Monte Carlo EGSnrc\BEAMnrc and EGS4\MCSIM were used in the comparison. The minimum segment size allowable during optimization had a direct impact on the number of monitor units calculated for each beam. Plans with the smallest minimum segment size (0.1 cm2 to 2.0 cm2) had the largest number of MUs. Although PTV coverage remained unaffected, the segment size did have an effect on the dose to the organs at risk. Pinnacle3-calculated PTV mean doses were in agreement with Monte Carlo-calculated mean doses to within 5.6% for all plans. On average, the mean dose difference between Monte Carlo and Pinnacle3 for all 88 plans was 1.38%. The largest discrepancy in maximum dose was 5.8%, and was noted for one of the plans using a minimum segment size of 1.0 cm2. For minimum dose to the PTV, a maximum discrepancy between Monte Carlo and Pinnacle3 was noted of 12.5% for a plan using a 6.0 cm2 minimum segment size. Agreement between point dose measurements and Pinnacle3-calculated doses were on average within 0.7% in both phantoms. The profiles show a good agreement between Pinnacle3, Monte Carlo, and EDR2 film. The gamma index and the isodose lines support the result.

Evaluation of PTW Seven29 for tomotherapy patient-specific quality assurance and comparison with ScandiDos Delta(4)

For routine quality assurance of helical tomotherapy plans, an alternative method, as opposed to the TomoTherapy suggested cylindrical solid water phantom with film and ionization chamber, is proposed using the PTW Seven29 2D-ARRAY inserted in a dedicated octagonal phantom, called Octavius. First, the sensitivity of the array to pitch was studied by varying the pitch during planning to 0.287, 0.433, 1.0, and 2.0. For each pitch selected, the dependence on field size was investigated by generating plans with field widths (FWs) of 1.06 cm, 2.49 cm, and 5.02 cm, for a total of 12 plans. Secondly, a total of 15 patient QA plans were delivered using helical tomotherapy with the Delta(4) and Seven29/Octavius for comparison. Using the clinical gamma criteria, 3% and 3 mm, all FW and pitch plans had a passing percentage of >90%. For patient QA plans, the average gamma pass percentage was 97.0% (94.4-99.8%) for the Delta(4) and 97.6% (92.5-100.0%) for the Seven29/Octavius. Both the Seven29/Octavius and Delta(4) performed to a high standard of measurement accuracy and had a 90% or greater gamma percent for all plans and were considered clinically acceptable.

Dosimetric impact of daily setup variations during treatment of canine nasal tumors using intensity-modulated radiation therapy

Intensity-modulated radiation therapy (IMRT) can be employed to yield precise dose distributions that tightly conform to targets and reduce high doses to normal structures by generating steep dose gradients. Because of these sharp gradients, daily setup variations may have an adverse effect on clinical outcome such that an adjacent normal structure may be overdosed and/or the target may be underdosed. This study provides a detailed analysis of the impact of daily setup variations on optimized IMRT canine nasal tumor treatment plans when variations are not accounted for due to the lack of image guidance. Setup histories of ten patients with nasal tumors previously treated using helical tomotherapy were replanned retrospectively to study the impact of daily setup variations on IMRT dose distributions. Daily setup shifts were applied to IMRT plans on a fraction-by-fraction basis. Using mattress immobilization and laser alignment, mean setup error magnitude in any single dimension was at least 2.5 mm (0-10.0 mm). With inclusions of all three translational coordinates, mean composite offset vector was 5.9 +/- 3.3 mm. Due to variations, a loss of equivalent uniform dose for target volumes of up to 5.6% was noted which corresponded to a potential loss in tumor control probability of 39.5%. Overdosing of eyes and brain was noted by increases in mean normalized total dose and highest normalized dose given to 2% of the volume. Findings suggest that successful implementation of canine nasal IMRT requires daily image guidance to ensure accurate delivery of precise IMRT distributions when non-rigid immobilization techniques are utilized. Unrecognized geographical misses may result in tumor recurrence and/or radiation toxicities to the eyes and brain.

Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study

PURPOSE

To evaluate the feasibility of using tomotherapy to deliver whole brain radiotherapy with hippocampal avoidance, hypothesized to reduce the risk of memory function decline, and simultaneously integrated boost to brain metastases to improve intracranial tumor control.

METHODS AND MATERIALS

Ten patients treated with radiosurgery and whole brain radiotherapy underwent repeat planning using tomotherapy with the original computed tomography scans and magnetic resonance imaging-computed tomography fusion-defined target and normal structure contours. The individually contoured hippocampus was used as a dose-limiting structure (<6 Gy); the whole brain dose was prescribed at 32.25 Gy to 95% in 15 fractions, and the simultaneous boost doses to individual brain metastases were 63 Gy to lesions >or=2.0 cm in the maximal diameter and 70.8 Gy to lesions <2.0 cm. The plans were generated with a field width (FW) of 2.5 cm and, in 5 patients, with a FW of 1.0 cm. The plans were compared regarding conformation number, prescription isodose/target volume ratio, target coverage, homogeneity index, and mean normalized total dose.

RESULTS

A 1.0-cm FW compared with a 2.5-cm FW significantly improved the dose distribution. The mean conformation number improved from 0.55 +/- 0.16 to 0.60 +/- 0.13. Whole brain homogeneity improved by 32% (p <0.001). The mean normalized total dose to the hippocampus was 5.9 +/- 1.3 Gy(2) and 5.8 +/- 1.9 Gy(2) for 2.5- and 1.0-cm FW, respectively. The mean treatment delivery time for the 2.5- and 1.0-cm FW plans was 10.2 +/- 1.0 and 21.8 +/- 1.8 min, respectively.

CONCLUSION

Composite tomotherapy plans achieved three objectives: homogeneous whole brain dose distribution equivalent to conventional whole brain radiotherapy; conformal hippocampal avoidance; and radiosurgically equivalent dose distributions to individual metastases.